Effects of comorbid conditions and prescribed chronic medications on the treatment plan for chronic hepatitis C infection: A cross-sectional retrospective study
- PMID: 38690003
- PMCID: PMC11056709
- DOI: 10.1002/hsr2.2055
Effects of comorbid conditions and prescribed chronic medications on the treatment plan for chronic hepatitis C infection: A cross-sectional retrospective study
Abstract
Background: Chronic hepatitis C (CHC) infection is a potentially life-threatening condition characterized by various complications, including end-stage liver disease and cirrhosis. The mortality rate associated with CHC has been increasing due to the presence of comorbidities and the use of chronic medications. Therefore, the objective of this study was to investigate the impact of these comorbidities and chronic medications on the treatment plan for CHC.
Methods: To achieve this objective, a cross-sectional retrospective study was conducted at a tertiary hospital in Jeddah, Saudi Arabia. The study population included patients aged 12 years and above who were diagnosed with CHC between 2016 and 2021. Patients below the age of 12 were excluded from the study. A total of 170 patients with CHC were included in the analysis. The study aimed to evaluate the relationship between CHC complications and the treatment approach.
Results: The mean age of the study participants was 66.78 years, with a higher proportion of female patients. The findings revealed a significant association between hypertension (p = 0.042) and cirrhosis (p = 0.007) with changes in the treatment plan for CHC. Moreover, the presence of diabetes mellitus (p = 0.045), renal diseases (p < 0.001), and hypothyroidism (p = 0.004) were significantly associated with HCV clearance after the initiation of therapy. Additionally, the use of proton pump inhibitors (p = 0.033) and levothyroxine (p = 0.025) was found to be associated with a higher rate of CHC clearance.
Conclusion: In conclusion, this study highlights the prevalence of comorbid conditions and the use of chronic medications among patients with CHC. The findings emphasize the importance of considering the effects of comorbidities and chronic medications when developing treatment plans for CHC infections. By taking these factors into account, healthcare professionals can optimize the management of CHC and improve patient outcomes.
Keywords: Saudi Arabia; chronic hepatitis C; clearance; comorbidities; cross‐sectional.
© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Chronic hepatitis C in saudi arabia: three years local experience in a university hospital.Hepat Mon. 2012 Sep;12(9):e6178. doi: 10.5812/hepatmon.6178. Epub 2012 Sep 30. Hepat Mon. 2012. PMID: 23087760 Free PMC article.
-
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare.BMC Public Health. 2024 Feb 20;24(1):532. doi: 10.1186/s12889-024-17851-0. BMC Public Health. 2024. PMID: 38378519 Free PMC article.
-
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND SYSTEMIC ARTERIAL HYPERTENSION ARE ASSOCIATED WITH HEPATIC NECROINFLAMMATORY ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C.Arq Gastroenterol. 2023 Jul-Sep;60(3):287-299. doi: 10.1590/S0004-2803.230302023-03. Arq Gastroenterol. 2023. PMID: 37792757
-
Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?Viruses. 2023 Dec 17;15(12):2451. doi: 10.3390/v15122451. Viruses. 2023. PMID: 38140692 Free PMC article. Review.
-
Consensus guidelines for the management of hepatitis C infection.Saudi Med J. 2003 Jul;24 Suppl 2:S99-118. Saudi Med J. 2003. PMID: 25121186
Cited by
-
Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study.Cureus. 2024 Aug 30;16(8):e68249. doi: 10.7759/cureus.68249. eCollection 2024 Aug. Cureus. 2024. PMID: 39350869 Free PMC article.
References
-
- Petta S, Craxì A. Extrahepatic manifestations of chronic viral C hepatitis. Gastroenterol Clin North Am. 2020;49(2):347‐360. - PubMed
-
- World Health Organization . Hepatitis C. 2023. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c2021
-
- Ministry of Health in Saudi Arabia . National Program to Eradicate HCV and Achieve the Global Objective. 2018. https://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/news-2018-04-0...
LinkOut - more resources
Full Text Sources